TY - JOUR
T1 - Vocal fold augmentation with calcium hydroxylapatite
T2 - Twelve-month report
AU - Rosen, Clark A.
AU - Gartner-Schmidt, Jackie
AU - Casiano, Roy
AU - Anderson, Timothy D.
AU - Johnson, Felicia
AU - Remacle, Marc
AU - Sataloff, Robert T.
AU - Abitbol, Jean
AU - Shaw, Gary
AU - Archer, Sanford
AU - Zraick, Richard I.
PY - 2009/5
Y1 - 2009/5
N2 - Objectives: To evaluate the long-term effectiveness of calcium hydroxylapatite (CaHA) vocal fold injection for patients with glottal insufficiency. Study Design: Multicenter, open-label, prospective clinical study of CaHA vocal fold injection. Methods: Each patient served as his/her own control. Voice-related outcome measures were collected for pre-injection, 1, 3, 6, and 12 months. Results: Sixty-three patients were available for evaluation. Fifty-three percent of the injection procedures were done in the office. Fifty-seven percent of patients were diagnosed with unilateral paralysis and 43% with glottal incompetence with mobile vocal folds. Patient satisfaction 12 months after injection showed 67% reporting a significant improvement in voice and 81% reporting at least a moderate improvement in voice. Utilizing the Voice Handicap Index-10, visual analog scale (vocal effort), Consensus Assessment Perceptual Evaluation V (judgments of voice severity), and objective voice measures of glottal closure (maximum phonation time and S:Z ratio), paired t tests showed significant improvements after treatment. A 22% further treatment rate was found at the 12-month time point. Conclusions: One-year results in this large cohort of patients with glottal incompetence treated with CaHA vocal fold injection demonstrate that excellent clinical results were achieved.
AB - Objectives: To evaluate the long-term effectiveness of calcium hydroxylapatite (CaHA) vocal fold injection for patients with glottal insufficiency. Study Design: Multicenter, open-label, prospective clinical study of CaHA vocal fold injection. Methods: Each patient served as his/her own control. Voice-related outcome measures were collected for pre-injection, 1, 3, 6, and 12 months. Results: Sixty-three patients were available for evaluation. Fifty-three percent of the injection procedures were done in the office. Fifty-seven percent of patients were diagnosed with unilateral paralysis and 43% with glottal incompetence with mobile vocal folds. Patient satisfaction 12 months after injection showed 67% reporting a significant improvement in voice and 81% reporting at least a moderate improvement in voice. Utilizing the Voice Handicap Index-10, visual analog scale (vocal effort), Consensus Assessment Perceptual Evaluation V (judgments of voice severity), and objective voice measures of glottal closure (maximum phonation time and S:Z ratio), paired t tests showed significant improvements after treatment. A 22% further treatment rate was found at the 12-month time point. Conclusions: One-year results in this large cohort of patients with glottal incompetence treated with CaHA vocal fold injection demonstrate that excellent clinical results were achieved.
KW - General otolaryngology
KW - Head and neck
KW - Quality of life
KW - Voice
UR - http://www.scopus.com/inward/record.url?scp=66349085906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66349085906&partnerID=8YFLogxK
U2 - 10.1002/lary.20126
DO - 10.1002/lary.20126
M3 - Article
C2 - 19274731
AN - SCOPUS:66349085906
SN - 0023-852X
VL - 119
SP - 1033
EP - 1041
JO - Laryngoscope
JF - Laryngoscope
IS - 5
ER -